Drug
Elesclomol sodium clinical trials
A product of Elesclomol; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
4 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Synta Pharmaceuticals Corp. (3) · GOG Foundation (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elesclomol sodium is read from its arms, and is right about nine times in ten.
Testing it · 4
- Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedPhase 2GOG FoundationNCT00888615Written as Elesclomol Sodium
- A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate CancerCompletedPhase 1Synta Pharmaceuticals Corp.NCT00808418Written as Elesclomol Sodium
- Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownPhase 1Synta Pharmaceuticals Corp.NCT01280786Written as Elesclomol Sodium
- A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid TumorsSuspendedPhase 1Synta Pharmaceuticals Corp.NCT00827203Written as Elesclomol Sodium
Codes
What other systems call elesclomol sodium · ClinicalTrials.gg INT017125
- NCI Thesaurus C79840Elesclomol SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C79840 | Elesclomol Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.